5-Hydroxytriptolide / Shanghai Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  5-Hydroxytriptolide / Shanghai Pharma
    A randomized controlled trial of (5R)-5-hydroxytriptolide in HIV INRs receiving ART (Poster Exhibition area) -  May 5, 2023 - Abstract #IASHIV2023IAS_HIV_206;    
    Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Shanghai Pharmaceuticals Holding Co., Ltd., and the National key technologies R&D program for the 13th five-year plan. Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
  • ||||||||||  5-Hydroxytriptolide / Shanghai Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=151, Completed, 
    Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Sep 2021 --> Jul 2022
  • ||||||||||  5-Hydroxytriptolide / Shanghai Pharma
    Enrollment closed:  Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients (clinicaltrials.gov) -  Nov 15, 2021   
    P2,  N=160, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Sep 2021 --> Jul 2022 Recruiting --> Active, not recruiting